IVF cycle (active assisted reproduction)
Active IVF or other ART cycle — REI-managed stimulation, monitoring, retrieval, and transfer. Distinct from preconception fertility-planning. Tight protocol timing leaves minimal room for adjuncts.
What changes during this transition
Active IVF cycles are physician-managed by reproductive endocrinology (REI). The protocol arc — pituitary suppression (GnRH agonist/antagonist) → controlled ovarian stimulation → trigger (hCG or GnRH-agonist trigger) → oocyte retrieval → fertilization (IVF or ICSI) → embryo transfer — runs on strict timing keyed to follicle counts, estradiol trajectory, and embryo-quality assessment. Patients adding peptides outside REI awareness risk interacting with stimulation pharmacology, masking response monitoring, or compromising luteal-phase and early-implantation windows in uncharacterized ways. The editorial register across this axis is REI-managed-or-not-at-all. The library carries this trigger primarily so users probing /ask in mid-cycle get honest answers — not as a discovery hub promoting peptide adjuncts. Kisspeptin is the singular peptide with real REI-relevant evidence (Abbara/Dhillo Imperial College trials of kisspeptin-54 as an oocyte-maturation trigger with lower OHSS risk vs hCG, particularly in PCOS and high-responder populations). GH adjuvants (rhGH, with CJC/ipamorelin as community extrapolation) have a contested meta-analytic signal in poor-responder protocols (Norman 2019, Bosdou 2020 Cochrane updates; ESHRE 2019 'consider' recommendation). Everything else in this axis is substrate-only — surfaced for honest /ask answers, not for discovery promotion.
Important caveat
Active IVF is a physician-managed protocol. Do NOT add peptides outside REI knowledge — protocol timing, trigger selection, luteal support, and embryo-transfer windows leave very little room for adjuncts and a real chance of disrupting cycle outcomes. Confirmed pregnancy (positive beta-hCG after transfer) is a HARD STOP for every peptide in this library without exception. Ovarian hyperstimulation syndrome (OHSS) is a serious cycle complication — peptides that affect fluid dynamics, vascular permeability, or coagulation are categorically wrong territory mid-cycle. Frozen embryo transfer (FET) cycles add programmed-estradiol and progesterone phases with their own constraints.
Peptides editorially relevant to ivf cycle (active assisted reproduction)
3 peptides from the library — each evidence-tiered honestly.
- KisspeptinTier 2
KISS1R agonist (hypothalamic neuropeptide)
Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.